Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534815 · ClinicalTrials.gov registry record · NA
Long-Term Treatment of Opioid Use Disorder
A NA study of Drug Addiction and Employment, sponsored by Northern Michigan University.
- Recruiting
- Registry status
- NA
- Development phase
- 225
- Enrollment target
- 1
- Study location
NCT05534815: Recruiting NA study of Drug Addiction and Employment, sponsored by Northern Michigan University.
NCT05534815 is a NA study of Drug Addiction and Employment that is actively recruiting participants, run by Northern Michigan University. The registered enrollment target is 225 participants, above the 91-participant average among 13 other Drug Addiction trials with a reported enrollment target (147% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05534815, a NA study of Drug Addiction and Employment, is actively recruiting participants, sponsored by Northern Michigan University.
- RECRUITING
- Registry status
- NA
- Development phase
- 225 participants
- Enrollment target
- 1
- Study location
Study Summary
Poverty and opioid addiction are interrelated and chronic problems which have not been addressed adequately. The Therapeutic Workplace could treat the many adults with opioid use disorder who are unemployed and live in poverty. The Therapeutic Workplace pays participants to work. To promote drug abstinence, the Therapeutic Workplace arranges employment-based abstinence reinforcement in which participants are required to provide drug-free urine samples to maintain maximum wages. Many studies have shown that employment-based abstinence reinforcement in the Therapeutic Workplace can promote and maintain drug abstinence. Recently, the investigators showed that abstinence-contingent wage supplements in the Therapeutic Workplace could promote drug abstinence and employment and reduce poverty. However, the investigators have not demonstrated the real-world impacts of the Therapeutic Workplace. The Therapeutic Workplace requires two modifications to produce real world impacts. 1. The investigators must develop a real-world version of the Therapeutic Workplace that community treatment programs can implement. 2. The investigators must reduce the costs of maintaining employment-based abstinence reinforcement. This application seeks to develop and evaluate a low-cost Therapeutic Workplace that community treatment programs can implement and that addresses the persistent nature of opioid addiction and poverty. The investigators propose to conduct a Stage III study in which a community clinic (REACH Health Services) adapts and implements the Therapeutic Workplace intervention. To improve the feasibility of this intervention, the investigators will use low-cost abstinence-contingent wage supplements to maintain abstinence. The investigators propose to conduct a randomized controlled study to evaluate the effectiveness of the low-cost abstinence-contingent wage supplements in a community Therapeutic Workplace to maintain long-term drug abstinence and employment, and to reduce pove
Primary Outcome
We will assess rate of urine samples negative for opioids (morphine, oxycodone, and fentanyl) and cocaine at the 4-week assessments during the Maintenance period. Y/N at each assessment).
Conditions Studied
Interventions
- BEHAVIORAL Employment-based abstinence reinforcement
Study Locations (1)
Michigan
- Northern Center for Learning and Health, Northern Michigan University, 1401 Presque Isle Ave. - Marquette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2028-02-29 |
| Phase | NA |
What NCT05534815 shows while recruiting
NCT05534815 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 91-participant average among 13 other Drug Addiction trials with a reported enrollment target (147% higher).
The record links to 2 conditions, with Drug Addiction appearing as the primary indexed condition, and to 1 intervention - of which Employment-based abstinence reinforcement is the first listed.
NCT05534815 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05534815 about?
NCT05534815 is a clinical study titled "Long-Term Treatment of Opioid Use Disorder". Poverty and opioid addiction are interrelated and chronic problems which have not been addressed adequately. The Therapeutic Workplace could treat the many adults with opioid use disorder who are unemployed and live in poverty. The Therapeutic Workplace pays participants to work. To promote drug abs...
What is the current status of trial NCT05534815?
This trial is currently recruiting. It is a NA study. The enrollment target is 225 participants. The study started on 2023-03-01. Estimated completion is 2028-02-29.
What conditions does trial NCT05534815 study?
This clinical trial studies the following conditions: Drug Addiction, Employment.
What interventions are being tested in trial NCT05534815?
The interventions under investigation include: Employment-based abstinence reinforcement (BEHAVIORAL).
Who is sponsoring clinical trial NCT05534815?
This trial is sponsored by Northern Michigan University, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05534815 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05534815's enrollment target sits among peer trials
225 1st of 13 higher than 13 of 13 other Drug Addiction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Drug Addiction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AWAITS: A Web-based E-health Application for Active Illicit Opioid Users
COMPLETED · NA
-
Innovative Digital Therapeutic for Smoking Cessation
COMPLETED · NA
-
Effects of MDMA on Social and Emotional Processing
COMPLETED · NA
-
Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3
COMPLETED · NA
-
Cannabidiol and Emotional Stimuli
COMPLETED · NA
-
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI